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Activation of the hypothalamic-pituitary-adrenal axis results in the release of hormones from the
adrenal glands, including glucocorticoids and mineralocorticoids. The physiological association be-
tween corticosteroids and cardiac disease is becoming increasingly recognized; however, the mecha-
nisms underlying this association are not well understood. To determine the biological effects of
corticosteroids on the heart, we investigated the impact of adrenalectomy in C57BL/6 male mice.
Animalswereadrenalectomized(ADX)at1monthofageandmaintainedfor3–6monthsafter surgery
to evaluate the effects of long-term adrenalectomy on cardiac function. Morphological evaluation
suggested that ADX mice showed significantly enlarged hearts compared with age-matched intact
controls. These changes in morphology correlated with deficits in left ventricular (LV) function and
electrocardiogram (ECG) abnormalities in ADX mice. Correlating with these functional defects, gene
expression analysis of ADX hearts revealed aberrant expression of a large cohort of genes associated
with cardiac hypertrophy and arrhythmia. Combined corticosterone and aldosterone replacement
treatment prevented the emergence of cardiac abnormalities in ADX mice, whereas corticosterone
replacement prevented the effects of adrenalectomyon LV function but did not block the emergence
of ECG alterations. Aldosterone replacement did not preserve the LV function but prevented ECG
abnormalities. Together, the data indicate that adrenal glucocorticoids andmineralocorticoids either
directly or indirectly have selective effects in the heart and their signaling pathways are essential in
maintaining normal cardiac function. (Endocrinology 157: 2759–2771, 2016)
Glucocorticoids andmineralocorticoids are secretedbythe cortex of the adrenal glands. Glucocorticoids
such as corticosterone (mice) and cortisol (humans) are
critical hormones for life, and their secretion is regulated
by the hypothalamic-pituitary-adrenal axis in a circadian
manner and in response to stress (1, 2). Mineralocortico-
ids (aldosterone) are released by the adrenal gland in re-
sponse to low blood volume or sodium depletion to reg-
ulate blood pressure (BP) (3). Both steroids act in a tissue-
specific manner by binding to their receptors, the
glucocorticoid receptor (GR) (Nuclear Receptor Subfam-
ily 3, Group C, Member 1; NR3C1) or the mineralocor-
ticoid receptor (MR) (Nuclear Receptor Subfamily 3,
Group C, Member 2; NR3C2), respectively (1, 2, 4, 5).
GR and MR are members of the nuclear receptor su-
perfamily of ligand-dependent transcription factors and
regulate the expression of numerous genes involved in
maintaining whole body homeostasis in response to al-
terations in metabolism and in stress (1, 4, 5). Conse-
quently, glucocorticoid and/or mineralocorticoid im-
balance, such as excess or deficiency, can result in a
variety of immunological, metabolic, and cardiovascu-
lar complications (6).
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Abbreviations: ADX, adrenalectomized; BNP, brain natriuretic peptide; BP, blood pressure;
CACNA1C, calcium channel, voltage-dependent, L type, 1C subunit; CACNA2D1, cal-
cium channel, voltage-dependent, 2/ subunit 1; CACNA2D2, calcium channel, voltage-
dependent, 2/ subunit 2; CACNB2, calcium channel, voltage-dependent, 2 subunit;
CV, coefficient of variation; ECG, electrocardiogram; FS, fractional shortening; GR, glu-
cocorticoid receptor; IPA, Ingenuity Pathway Analysis; LV, left ventricle; LVD, LV dysfunc-
tion; LVEDD, LV internal diameter at diastole; LVESD, LV internal diameter at systole;
MHC, -myosin heavy chain; MR, mineralocorticoid receptor; PR, P-R interval; RYR2,
ryanodine receptor 2; SERCA2, SR calcium transport ATPase 2; SKA, skeletal muscle -ac-
tin; SLC8A1, solute carrier family 8 (sodium/calcium exchanger), member 1; SR, sarco(en-
do)plasmic reticulum.
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Primary adrenal insufficiency is an endocrine disorder
characterized by insufficient secretion of glucocorticoids,
and often mineralocorticoids (7–9). Despite clinical data
suggesting that patients with adrenal insufficiency can de-
velop cardiac complications, limited information exists on
the biological actions of glucocorticoids andmineralocor-
ticoids in maintaining normal cardiac function (10). Ad-
dison’s disease, themost common formofprimaryadrenal
insufficiency, was characterized more than 160 years ago
by Thomas Addison, who described that among the lead-
ing features of patients suffering from adrenal disease was
a remarkable feebleness of the heart actions (11). Subse-
quent investigations revealed thatdecreasedproductionof
corticosteroids by the adrenal gland can lead to cardiac
complications, including systolic failure and significant
reduction in stroke volume (10, 12). Studies performed on
isolated cardiac papillary muscle from adrenalectomized
(ADX) rats suggested that corticosteroids regulate thegen-
eration of mechanical force in the heart (13, 14). In addi-
tion, several clinical studies in patients with heart failure
have shown the existence of a correlation between both
cortisol and aldosterone plasma levels and mortality (15–
17), which are consistent with potential effects of corti-
costeroids on myocardial function. Furthermore, in vitro
studies have shown that glucocorticoids andmineralocor-
ticoids exert direct effects in cardiomyocytes (18–20). Re-
cent evidence found in transgenic mouse models have
shown that prenatal inactivation of GR signaling in the
heart leads to major structural and functional alterations
in the maturation of the fetal heart (21). In addition, tar-
geted deletion of GR in cardiomyocytes has demonstrated
that intactGR signaling is critical for normal cardiac func-
tion and viability in adult mice (22). In contrast, under
normal physiological conditions, cardiomyocyte MR ap-
pears to be nonessential for cardiac hemodynamics, struc-
ture or function (23, 24); however, blockade of MR pro-
tects the heart from injury in mouse models (23, 25), and
prevents heart failure associated with myocardial infarc-
tion in humans (26). Although, these results suggest that
both GR and MR play significant roles in cardiac physi-
ology and pathology, the nature of the ligand mediating
the observed phenotypes remains unclear. The goal of the
present study was to investigate the role of endogenous
corticosteroids in the modulation of cardiac function in
vivo in ADXC57BL/6 male mice. Our findings show that
glucocorticoids have a primary role in the modulation of
cardiac gene expression and function, whereas mineralo-
corticoids seem to be critical in the regulation of cardiac
electrical function.
Materials and Methods
Animals
1-month-old male intact (control, no surgical intervention),
sham-ADX,andADXC57BL/6micewerepurchased fromCharles
River Laboratories. One week after surgery, ADX mice were
shipped to our facility, and upon arrival, all ADXmicewere placed
on0.154Msodiumchloride solution.One set of control and sham-
ADX mice were also maintained on regular drinking water,
whereas a second set was maintained on 0.154M sodium chloride
solution.All studieswereperformedonmalemice.Allanimalswere
maintained in accordance with the National Institutes of Health
directives for the care and use of laboratory animals. These studies
were approved by the National Institute of Environmental Health
Sciences’ Animal Care and Use Committee.
Corticosterone, epinephrine, and aldosterone
plasma levels
Blood samples from experimental animals were obtained by
retroorbital sinus puncture using EDTAmicrohematocrit tubes.
Blood samples were collected between 9 and 11:30 AM. Corti-
costerone, epinephrine, and aldosterone plasma levelsweremea-
sured by commercially available ELISAs following themanufac-
turer’s instructions (DetectX Corticosterone Enzyme Arbor
assays; Aldosterone ELISA kit, Abcam; Eagle Biosciences). The
intra- and interassay coefficients of variation (CVs) for the cor-
ticosterone assaywere 6.3%and 9.9%, 6.6%and 10.8% for the
aldosterone assay, and 9.0% and 7.7% for the epinephrine as-
say. All samples were assayed in duplicate. For the first cohort of
miceused in this study (Figures1–7andTable1), themeanvalues
for corticosterone and aldosterone in intact mice (1–6 mo) were
Figure 1. Plasma levels of corticosterone (A), aldosterone (B), and epinephrine (C) in control (intact adrenal glands) and ADX mice. Hormone
levels were measured at 1, 3, and 6 months after adrenalectomy. Data are mean  SEM (n  10 mice per group). *, P  .05; **, P  .01;
***, P  .001 vs control mice.
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between 15–36 and 0.03–0.08 ng/mL, respectively, whereas
mean values for corticosterone and aldosterone in ADX mice
was 3–9 and 0.0–0.005 ng/mL, respectively. During the interval
between our initial studies and the hormone replacement studies
(Figures 8 and 9 and Table 2) our animal facility underwent
changes in animal housing, which likely influenced the baseline
for corticosterone levels. In this second cohort of mice the mean
values for corticosteroneandaldosterone in intactmicewere126
15 and 0.04  0.01 ng/mL, respectively. For ADX mice in the
second cohort of mice, the mean values for corticosterone and al-
dosterone were 21 14 and 0.005 0.0001 ng/mL, respectively.
Despite the observed increase in corticosterone levels in both intact
and ADXmice, corticosterone levels remained statistically signifi-
cantly decreased in ADX mice (P .001) in both studies.
Plasma electrolytes levels and liver panel
Na, K, Cl, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), total bile acids (TBA), and sorbitol
dehydrogenase (SDH) plasma levels were determined with the
Olympus AU400e clinical analyzer, BeckmanCoulter, Inc fol-
lowing themanufacturer’s instructions. All reagentswere pur-
chased from Beckman Coulter, Inc.
Echocardiographic analysis
Transthoracic echocardiography was performed on con-
sciousmicewith aVisualSonicsVevo 770 ultrasound biomicros-
copy system (VisualSonics, Inc) with a 30-MHx 707B scan head
as previously described (22). Briefly, 2-dimensional guided M-
mode analysis of the left ventricle (LV) was performed on intact
(controls) andADXmice from 1 to 6months of age. The leading
edges of the epicardium and endocardiumwere used to measure
anteriorwall thickness, posteriorwall thickness, andLV internal
diameters (LV internal diameter at diastole [LVEDD], LV inter-
nal diameter at systole [LVESD]). LV volume in diastole was
calculated from the equation LV volume in diastole  (7/2.4 
LVEDD)  LVEDD3  1000, and LV volume in systole was
calculated from the equation LV volume
in systole  (7/2.4  LVESD) 
LVESD3  1000. LV systolic function
was assessed by fractional shortening
(FS), calculated from the equation FS%
 (LVEDD  LVESD)/LVEDD  100.
M-mode measurements represent 3 av-
erage consecutive cardiac cycles from
each mouse.
Electrocardiographic analysis
Electrocardiographs were recorded
from conscious mice with the noninva-
sive ECGenie recording platform
(Mouse Specifics, Inc) as previously de-
scribed (22, 27). Briefly, mice were po-
sitioned on the electrocardiogram (ECG)
recording platform. Data were analyzed
with the EzCG ECG analysis software
(Mouse Specifics, Inc).
BP measurements
BP was measured with a tail-cuff sys-
tem(CODA-6;Kent Scientific) following
the manufacturer’s instructions. Briefly,
conscious animalswere preheated in a heating cabinet for 20–30
minutes at 32°C. At least 10 accurate measurements per animal
were used for analysis of diastolic, mean, and systolic pressure.
Real-time PCR (RT-PCR)
Total RNAwas isolated from thewhole hearts of intact (con-
trol) and ADX C57BL/6 mice with the RNeasy Mini kit and
RNase-Free DNase kit (QIAGEN) according to the manufac-
turer’s instructions. mRNA levels were determined with a
CFX96 Real-Time System C1000 Touch Thermal Cycler (Bio-
Rad). Predesigned primer/probe sets for GR, ACTA1 (skeletal
muscle-actin [SKA]),MYH7(-myosinheavy chain [MHC]),
NPPB (brain natriuretic peptide [BNP]), ATP2A2 (sarco[endo-
]plasmic reticulum [SR] calcium transportATPase 2 [SERCA2]),
solute carrier family 8 (sodium/calcium exchanger), member 1
(SLC8A1), ryanodine receptor 2 (RYR2), calcium channel, volt-
age-dependent,L type,1Csubunit (CACNA1C), calciumchan-
nel, voltage-dependent, 2/ subunit 1 (CACNA2D1), calcium
channel, voltage-dependent, 2/ subunit 2 (CACNA2D2),
CACNA1G, and cyclophilin B (peptidylprolyl isomerase B)were
obtained from Applied Biosystems. Values measured for each
primer/probe set were normalized to cyclophilin B.
Histological analysis
Hearts from intact andADXmicewereperfusedwithPBSand
fixed with freshly prepared 4% paraformaldehyde. Samples
were processed, embedded in paraffin, cut in 5 m sections, and
stained with hematoxylin-eosin.
Cross-sectional area analysis of cardiomyocytes
Paraffin sections were stained with fluorescently labeled lec-
tin as previously described (28). For cross-sectional area analysis
of cardiomyocytes, TRITC-conjugated lectin (Triticumvulgaris;
Sigma-Aldrich) staining was performed and measured as previ-
ously described and examined by fluorescence microscopy (28).
Figure 2. Long-term adrenalectomy leads to a significant decrease in cardiac performance. A,
Representative M-mode images from age-matched intact (control) and ADX mice at 6 months
after surgery. B, Transthoracic echocardiography on conscious male C57BL/6 ADX and age-
matched controls at 6 months after ADX. IVSTD, anterior wall thickness at diastole; IVSTS,
anterior wall thickness at systole; PWTD, PWT at diastole; PWTS, PWT at systole; LV VolD, LV
volume in diastole; LV VolS, LV volume in systole; TL, tibia length; HW, heart weight; BW, body
weight; HR, heart rate. Data are  SEM (n  15 mice per group). A Student’s t test was
performed to determine statistical significance (P  .05).
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Microarray analysis
Gene expression analyses were performed on RNA from the
hearts of long-term ADXmice (6 mo) and age matched controls
with the Agilent Whole Mouse Genome oligo arrays (014868)
(Agilent Technologies) following the Agilent 1-color microar-
ray-based gene expression analysis protocol as described previ-
ously (22). Briefly, data were obtained by the Agilent Feature
Extraction software (v9.5), with the 1-color defaults for all pa-
rameters. The Agilent Feature Extraction Software performed
error modeling, adjusting for additive and multiplicative noise.
The microarray data will be available in the Gene Expression
Omnibus repository at the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/geo/info/link-
ing.html). To further analyze the microarray datasets, the data
were processed viaAgi4x44PreProcess andBioconductor for the
R software environment (www.rproject.org). A single log scale
normalized expression measure for each probe set was obtained
after background correction and normalization between sam-
ples. Box plots, density plots,MA plot, and spatial images of the
raw and normalized data were examined in order to check the
quality of the microarray data, and that no unusual results for
any slide were observed. Principal component analysis was per-
formedonall samples andall probes to reduce thedimensionality
of the data while preserving the variation in the dataset. This
Figure 4. Dysregulation of genes associated to cardiac hypertrophy in long-term ADX mice. A–C, RT-PCR analysis of MHC, SKA, and BNP mRNA
from hearts of control (intact) and long-term (6 mo) ADX mice. Values are normalized to cyclophilin (PPIB) mRNA. Data are mean  SEM (n  6
mice per group). **, P  .01 vs control mice. This PCR study is independent from the microarray data.
Figure 3. Adrenalectomy leads to changes in heart morphology and cardiomyocyte size. A, Representative images of intact hearts from age-
matched control (intact) and long-term ADX male mice (6 mo after surgery). B, Representative images of H&E-stained sections of control and long-
term ADX mice. C, Representative images of TRITC-lectin staining of cardiomyocytes from control and long-term ADX mice. D, Morphometric
analysis of cardiomyocyte cross-sectional area. Data are mean  SEM (n  10 mice per group). Scale bar, 50 m. A Student’s t test was
performed to determine statistical significance (*, P  .05).
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allowed us to assess the similarities and differences of samples
within a treatment group and between treatment groups. The
significance of the log ratio for each probe was determined by
calculating one modified t statistic per probe using an empirical
Bayesian approach. Probes with Benjamini-Hochberg multiple
test corrected P  0.05 were considered to be differentially ex-
pressed for comparison of the groups. The lists of probe sets
generated were analyzed with the Pathway Analysis version 6.5
(Ingenuity Systems).
Corticosterone, aldosterone, and betamethasone
treatments
Corticosterone, aldosterone, and betamethasone were given
in 0.154M sodium chloride water at final concentrations of 25,
0.3, and 2.5 g/mL, respectively, as previously described (29–
32). Corticosterone, aldosterone, and betamethasone were pur-
chased from Steraloids. Male C57BL/6 mice were ADX at 1
month of age and treated with corticosterone, betamethasone,
aldosterone, or vehicle (PBS) in saline water for 3 months.
Statistical analysis
Statistics were performed with the GraphPad Prism software
v6 (GraphPad Software, Inc). Student’s t test (intact vs ADX
mice) or one-way ANOVA with multiple comparisons analysis
(intact vs ADX, ADX-corticosterone, ADX-aldosterone, ADX-
corticosterone/aldosterone, and ADX-betamethasone) were
used to evaluate whether differences between groups were sta-
tistically significant. Differences were considered to be statisti-
cally significant whenP .05. For all studies we used 6–15mice
per group, with the exception of ECG data on 6-month ADX
mice (n  4).
Results
Plasma levels of corticosteroids, catecholamines,
and electrolytes in controls (intact) and ADX male
mice
In order to evaluate whether surgical removal of the
adrenal glands leads to a sustained decrease in circulating
corticosteroids and catecholamines, blood samples from
controls and ADX mice were collected. Surgical adrenal
ablation in ADX mice was confirmed during tissue har-
vesting. Only mice with confirmed adrenal ablation were
included in this study. Endogenous corticosterone, aldo-
sterone, and epinephrine plasma levels were evaluated 1,
3, and 6 months after surgery. Our data show that corti-
costerone, aldosterone, and epinephrine plasma levels
were significantly diminished in ADX mice as compared
with controls from 1 to 6 months after surgery (Figure 1,
A–C).
Cardiac performance and heart morphology in
long-term ADX mice
To understand the role of adrenal hormones in the eti-
ology of heart disease, the chronic effects of adrenal in-
sufficiency were evaluated in conscious ADX mice by
transthoracic echocardiography. No major differences
were observed between controls (intact) and ADXmice 1
month after adrenalectomy (Supplemental Figure 1).
However, differences in cardiac function were detected
between control and ADX mice 6 months after surgery
(Figure 2A). Six-month ADX mice exhibited compro-
mised LV function, as evidenced by a significant decrease
in FS (59.65% control vs 50.96% ADX) (Figure 2B). In
Figure 5. Global gene expression profiles of long-term ADX hearts.
Microarray analyses were performed on RNA from the hearts of age-
matched male controls (intact) and ADX mice (6 mo after surgery). A,
Total number of genes differentially expressed in the hearts of ADX
mice compared with aged-matched controls: of the 2400 significant
altered genes identified, 40% (971 genes) were induced, and 60%
(1469 genes) were repressed in ADX hearts. Red and green colors
correspond to induced and repressed expression, respectively. B,
Differentially expressed genes were analyzed by IPA software for each
age group. Shown are the top 10 biological functions most
significantly associated with the genes differentially regulated in the
hearts of ADX mice. C, Most significant disorders or functions
associated with the cardiovascular disease dysregulated genes in ADX
hearts.
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addition, we found that both heart weight and LV mass
normalized to tibia length were significantly elevated in
6-month ADX mice (Figure 2B).
To evaluate the etiology of the LV dysfunction (LVD)
observed in the long-term ADX mice, hearts were col-
lected and analyzed by histology. Gross morphological
evaluation suggested that 6-month ADX mice had signif-
icantly enlarged hearts compared with age-matched con-
trols (Figure 3A). In agreement with these observations,
histological evaluation of hematoxylin-eosin-stained
Figure 6. IPA identified that genes involved in cardiovascular disease were associated with ventricular tachycardia (13 genes), heart dysfunction
(50 genes), and failure (12 genes). Among the dysregulated genes in these 3 categories we found RYR2, CACNB2, CACNA1C, CACNA2D1,
CACNA2D2, SLC8A1, and a Ca transporting, cardiac muscle, slow twitch ATPase (ATP2A2 or SERCA2). These genes are marked by a red
asterisk (*). Red and green colors correspond to induced and repressed expression, respectively.
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heart sections showed an increase in the thickness of the
LVwall of the6-monthADXmice (Figure3B). Supporting
these findings, a significant (P .05) approximately 20%
increase in cardiomyocyte cross-sectional area (Figure3,C
and D) was detected in TRITC-stained ADX heart sec-
tions. These data suggest that long-term adrenalectomy
leads to impairment of cardiac function associated with
changes inheartmorphology, as evidencedbya thickening
of the myocardium of the LV and an increase in the cross-
sectional area of the cardiomyocytes of ADX hearts. Be-
cause control mice were maintained on regular drinking
water, plasma electrolyte levelsweremeasured to evaluate
whether electrolyte abnormalities were secondary con-
tributors to the cardiac phenotype observed in ADXmice.
Plasma electrolyte levels did not differ between control
(regular drinking water) and ADX (saline solution) mice
(Supplemental Figure 2). In addition, no significant ab-
normalities in BP were observed in ADX mice compared
with control mice (Supplemental Figure 3). Moreover, in-
tact and sham-ADX groups of mice that were maintained
on 0.154M sodium chloride showed no significant alter-
ations in BP (Supplemental Figure 3), LV function (Sup-
plemental Figure 4), or heart electrical activity (Supple-
mental Table 1). Therefore, the cardiac phenotype
observed in ADX mice is likely an effect of corticosteroid
deficiency and is likely not associated with the 0.154M
sodium chloride drinking water.
Effects of long-term adrenalectomy in the
expression of cardiac stress marker genes
In order to dissect the molecular basis of the impaired
heart function observed in the long-termADXmice and to
evaluate whether those changes corresponded to changes
in gene expression observed in pathological cardiac hy-
pertrophy, we evaluated mRNA levels of cardiac MHC,
SKA, and BNP in the hearts of 6-month ADX and intact
mice. A 4.32-fold increase in MHC and a 3.08-fold in-
crease SKA (Figure 4, A and B)were found inADXhearts.
In addition,wemeasured a2.84-fold increase inBNP (Fig-
ure 4C). These data suggest that the compromised cardiac
function and the increase in LV thickness in long-term
ADX mice are pathological.
Figure 7. Down-regulation of genes involved in calcium signaling the
hearts of ADX mice. Total RNA was isolated from whole hearts of
control and ADX mice (6 mo after surgery). CACNB2, CACNA1C1,
CACNA2D1, CACNA2D2, RyR2, cardiac troponin T type 2, and
SERCA2 mRNA levels were measured by qPCR. Data are mean  SEM
(n  6 mice per group). *, P  .05; **, P  .01; ***, P  .001 vs
control mice.
Table 1. Electrocardiographic Analysis of Conscious
C57BL/6 ADX and Age-Matched Controls at 6 Months
After ADX (SEM)
Control ADX
HR, bpm 762.75  6.10 756.8  7.85
HRV, bpm 12.95  4.15 10.18  2.11
CV, % 1.70  0.56 1.348  0.28
RR, ms 78.75  0.62 79.32  0.83
PQ, ms 17.5  0.49 18.98  1.05
PR, ms 23.92  0.24 25.4  0.92
QRS, ms 10.25  0.32 10.74  0.36
QT, ms 39.92  0.29 42.02  0.19b
ST, ms 30.2  0.27 31.8  0.35a
QTc, ms 45.05  0.35 47.2  0.39b
QT Disp, ms 19.5  1.76 15.2  2.49
QTc Disp, ms 22.32  2.03 17.26  2.64
Mean SR amplitude, V 0.975  0.12 1.06  0.13
Mean R amplitude, V 0.66  0.04 0.85  0.13
rMSSD, ms 1.97  0.71 0.93  0.09
pNN50 (6 ms), % 1.92  1.710 0
HR, heart rate; HRV, HR variability; RR, R-R interval; PQ, P-Q interval;
QRS, QRS complex; QT, QT Disp, maximum QT interval minus
minimum QT interval; ST, ST segment; QTc Disp, HR corrected QT
interval; rMSSD, root mean square successive difference in heart
period; pNN50, measure of HR variability. A Student’s t test was
performed to determine significance. Values without asterisk were not
significant different. n  4 mice per group.
a P  .05 vs control mice.
b P  .01 vs control mice.
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Genome-wide cardiac gene expression profile of
long-term ADX hearts
To define the molecular events and pathways underly-
ing the effects of adrenalectomy in our model, genome-
wide microarray analysis was performed on hearts from
intact and ADX mice (6 mo). Adrenalectomy resulted in
the differential expression of 2440 genes in the hearts of
ADX mice (Supplemental Table 2). Interestingly, the ex-
pression of most these genes was repressed in response to
long-term adrenalectomy. Specifically, we discovered that
971 genes were induced, whereas 1469 genes were re-
pressed in the hearts of ADXmice (Figure 5A). These find-
ings suggest that adrenal hormones are either directly or
indirectly essential in maintaining normal cardiac gene
expression.
To determine the significance of the changes observed
in the cardiac transcriptomeof long-termADXmice, 2440
genes were analyzed by literature-based Ingenuity Path-
way Analysis (IPA) software. The analysis identified “car-
diovascular disease” as one of the top 10 biological func-
tions most significantly affected by the altered gene
expression pattern in the heart of ADX mice (Figure 5B).
A total of 135 genes associated with cardiovascular dis-
easewere dysregulated inADXhearts (Figure 5B and Sup-
plemental Table 3). Further analysis of these 135 genes
showed that 13, 50, and 12 of these genes were associated
with ventricular tachycardia, heart dysfunction, and heart
failure, respectively (Figures 5C and 6 and Supplemental
Table 4). Among the genes found in these categories were
RYR2, calcium channel, voltage-dependent, 2 subunit
(CACNB2), CACNA1C, CACNA2D1, CACNA2D2,
SLC8A1, and cardiac troponin T type 2 (Figure 6).
The changes in gene expression were further validated
by RT-PCR. For this purpose, we used hearts from addi-
tional long-term ADX mice that were independent from
those employed in themicroarray studies. Consistentwith
the microarray data, the expression of all 7 genes was
significantly repressed in the hearts of ADX mice (Figure
7). In addition, we found that the cardiac mRNA levels of
SERCA2 were also significantly repressed in the hearts of
ADX mice (Figure 7). These data indicate that long-term
adrenal insufficiency leads to dysregulation of genes in-
volved in regulating calcium handling and contractile
function of the heart.
ECGs in long-term ADX mice
In order to assess whether the changes in gene expres-
sion profiles displayed by long-term ADXmice translated
Figure 8. Hormone replacement effects on cardiac function in ADX mice. A, Representative M-mode images from age-matched intact (control),
ADX, and corticosterone-ADX (cort, 25 g/mL)-treated mice, aldosterone-ADX-treated mice (aldo, 0.3 g/mL), corticosterone/aldosterone-treated
mice, and betamethasone-ADX (Beta, 2.5 g/mL)-treated mice. B, Transthoracic echocardiography on conscious C57BL/6 hormone-treated ADX
mice, ADX, and age-matched controls at 3 months after ADX. Data are mean  SEM (n  8–12 mice per group). IVSTD, anterior wall thickness at
diastole; IVSTS, anterior wall thickness at systole; PWTD, PWT at diastole; PWTS, PWT at systole; LV VolD, LV volume in diastole; LV VolS, LV
volume in systole; TL, tibia length; HW, heart weight; BW, body weight; HR, heart rate. One-way ANOVA with multiple comparisons was
performed to determine significance between groups (P  .05).
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into abnormalities in the electrical conduction system of
the heart, ECGswere performed on intact and ADXmice.
We used a noninvasive system to record ECGs in ADX
mice 6 months after surgery. All mice were conscious,
unsedated, and unrestrained. No differences were de-
tected in average heart rates between control and ADX
mice (controls 762.75 6.10 bpm vs ADX 756.8 7.85
bpm). In addition, adrenalectomy had no effects on P-R
Table 2. Electrocardiographic Analysis of Conscious C57BL/6 Hormone-Treated ADX, Age-Matched ADX, and
Controls at 3 Months After ADX (SEM)
Control ADX Cort Aldo Cort/Aldo Beta
HR, bpm 733.22  13.02 720.55  15.95 724.57  16.42 703.08  14.09 717.81  9.43 707.5  12.11
HRV, bpm 24.77  3.93 31.84  8.72 29.68  7.79 27.41  4.77 26.36  7.06 32.38  6.71
CV, % 3.41  0.54 4.48  1.26 4.15  1.08 3.97  0.75 3.60  0.92 4.67  0.9
RR, ms 82.17  1.62 83.86  1.96 83.37  1.97 85.93  1.82 83.94  1.08 85.23  1.49
PQ, ms 19.1  0.57 18.4  0.44 18.87  0.59 19.13  0.71 17.35  0.54 20.66  0.68
PR, ms 25.01  0.68 24.87  0.60 25.6  0.59 24.95  0.58 23.49  0.50 26.95  0.76
QRS, ms 10.05  0.29 11.61  0.29b 11.1  0.12b 10.20  0.27 10.19  0.27 10.77  0.34
QT, ms 39.86  0.36 43.26  0.97* 42.72  0.75a 41.79  0.66 41.56  0.81 42.43  0.34a
ST, ms 30.43  0.27 32.18  0.70 32.12  0.67 32.07  0.68 31.87  0.78 32.15  0.51
QTc, ms 44.46  0.43 47.18  0.81a 46.95  0.58a 45.1  0.53 45.37  0.77 46.06  0.44a
QT Disp, ms 22.25  1.51 25.56  3.13 21.85  4.41 25.29  1.04 23.68  2.02 21.31  2.83
QTc Disp, ms 25.41  1.76 27.32  3.57 24.01  4.84 26.67  0.84 25.27  2.01 22.55  2.81
Mean SR amplitude, V 0.87  0.10 0.73  0.10 0.88  0.11 0.91  0.10 1.00  0.09 1.11  0.11
Mean R amplitude, V 0.65  0.06 0.63  0.06 0.73  0.09 0.71  0.08 0.72  0.06 0.88  0.12
rMSSD, ms 2.62  0.40 4.15  1.56 4.0  1.87 2.61  0.52 2.59  0.45 2.52  0.42
pNN50 (6 ms), % 4.04  1.27 1.23  1.06 5.67  2.29 4.78  2.13 7.62  4.97 8.91  3.36
Cort, corticosterone; Beta, betamethasone; Aldo, aldosterone; HR, heart rate; HRV, HR variability; RR, R-R interval; PQ, P-Q interval; QRS, QRS
complex; QT, QT Disp, maximum QT interval minus minimum QT interval; ST, ST segment; QTc dispersion, HR corrected QT interval; rMSSD, root
mean square successive difference in heart period; pNN50, measure of HR variability. One-way ANOVA with multiple comparisons was performed
to determine significance between groups (P  .05). n  8–12 mice per group.
a P  .05 vs control mice.
b P  .01 vs control mice.
Figure 9. RT-PCR analysis of MHC, SKA, CACNA1C1, CACNA2D1, and RYR2 mRNA from hearts of control, ADX, and corticosterone-treated
ADX mice. Values are normalized to cyclophilin (PPIB) mRNA. Data are mean  SEM (n  6 mice per group). One-way ANOVA was performed to
determine significance between groups. *, P  .05; **, P  .01; ***, P  .001; n.s., not significant.
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interval (PR) (controls 23.92 0.24 vs ADX 25.4 0.92
ms) and QRS interval (controls 10.25  0.32 vs ADX
10.74 0.36) (Table 1). Interestingly, QT (39.92 0.29
vs 42.02 0.19 ms), ST (30.2 0.27 vs 31.8 0.35 ms)
andQTc intervals (45.05 0.35 vs 47.2 0.39 ms) were
significantly prolonged in ADX mice (Table 1). These
findings suggest that adrenal insufficiency also leads to
alterations in the electrical depolarization and repolariza-
tion of the ventricles, which increases the risk of develop-
ing ventricular arrhythmias. Moreover, these results cor-
relate with microarray data showing the dysregulation of
several voltage-gated calcium channels and other genes
involved in the regulation of cardiac action potential.
Effects of corticosterone treatment on cardiac
gene expression, LV function, and electrical
activity
To determine whether glucocorticoids were responsi-
ble for the effects of adrenalectomy in cardiac gene ex-
pression and function in our model, male C57BL/6 mice
were ADX at 1 month of age and treated with corticoste-
rone (25 g/mL) in 0.154MNaCl for 3 months. Cortico-
sterone-treated ADX mice reached similar corticosterone
plasma levels to those observed in intact mice (126  15
control vs 153  9 ng/mL corticosterone-treated ADX)
(Supplemental Figure 5A), and in ADX mice, corticoste-
rone levels were statistically significantly decreased (P 
.0001) when compared with intact or corticosterone-
treated ADXmice (Supplemental Figure 5). Cardiac func-
tion was evaluated by conscious transthoracic echocardi-
ography.Corticosterone treatment significantly improved
LV function in ADX mice (Figure 8A). No major differ-
ences were observed between control (intact) and corti-
costerone-treated ADX mice (Figure 8B). Remarkably,
corticosterone treatment also prevented increases in the
gene expression of cardiacMHCand SKA in the heart of
corticosterone-treated ADXmice (Figure 9A). Moreover,
gene expression of CACNA1C, CACNA2D1, and RYR2
was significantly improved in corticosterone-ADX hearts
as comparedwith untreated ADXmice (Figure 9B). These
findings demonstrate that corticosterone play an impor-
tant role in the regulation of cardiac gene regulation and
are essential for the prevention of LVD in ADXmice. We
also assessed whether corticosterone treatment prevented
abnormalities in cardiac conduction displayed by long-
term ADXmice. No differences in average heart rate, PR,
QRS, or any other parameter were found between intact
controls and ADX-corticosterone-treated mice (Table 2).
However, QT and QTc remained significantly prolonged
in corticosterone-treated ADX mice. Therefore, cortico-
sterone treatment was not sufficient to prevent the emer-
gence of ECG abnormalities in ADX mice.
Effects of aldosterone, corticosterone/aldosterone,
and betamethasone treatment on LV function and
electrical activity in ADX mice
Corticosterone has been reported to have a 10- to 30-
fold lower affinity for GR than MR, thus to differentiate
between glucocorticoid and mineralocorticoid effects in
our model, ADX mice were treated with aldosterone (0.3
g/mL), corticosterone (25 g/mL)/aldosterone (0.3 g/
mL), or the GR selective ligand betamethasone (2.5 g/
mL) in 0.154M NaCl for 3 months after surgery. Aldo-
sterone plasma levels were also restored to comparable
levels with those found in intact mice (0.044 0.01 con-
trol vs0.040.01ng/mLaldosterone-treatedADX) (Sup-
plemental Figure 5B).
Cardiac function was evaluated by echocardiography.
Despite betamethasone effects on growth and body
weight, the treatment significantly improved LV function
inADXmice (Figure 8, A andB), and nomajor differences
were observed between control (intact) and corticoste-
rone/aldosterone or betamethasone-treated ADX mice
(Figure8B).Aldosterone alonedidnot restoreLV function
in ADX mice, whereas the combined treatment of corti-
costerone and aldosterone prevented LVD in ADX mice
(Figure 8, A and B). No significant effects in serum elec-
trolyte levels were found in corticosterone- or betametha-
sone-treated ADX mice (Supplemental Figure 2); how-
ever, serum potassium levels were lower in the
aldosterone-treated ADX mice (Supplemental Figure 2).
Lowerpotassium levels (hypokalemia) havebeen reported
to be associatedwith prolongedQT intervals (33).Despite
the decrease in serum potassium levels, aldosterone re-
placement treatment prevented the emergence of ECG ab-
normalities in ADX mice (Table 2). In addition, ECG ab-
normalities were also blocked by the combined treatment
of corticosterone and aldosterone (Table 2). In contrast,
QT and QTc intervals remained prolonged in betametha-
sone-treated ADXmice (Table 2). To investigate whether
changes in BP contributed to the changes in LV function
and ECG, BP was measured in hormone-treated ADX
mice. Hormone treatments did not altered BP in this
mouse model (Supplemental Figure 3). Thus, the increase
inhypertrophyobserved in aldosterone-treatedmice is not
likely a secondary effect of high BP.
Discussion
Corticosteroids can exert significant effects on heart func-
tion; however, it is unclearwhether their actions are direct
or indirect andwhether they aremediated through theGR
or the closely related MR. The purpose of this study was
to elucidate the role of endogenous corticosteroids in the
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modulation of cardiac function. To achieve this goal we
performed studies on long-termADXmaleC57BL/6mice.
Our data demonstrate that glucocorticoids and mineralo-
corticoids exert selective effects in the heart, with gluco-
corticoid signaling playing a preponderant role in the reg-
ulation of LV function and cardiac gene expression,
whereas mineralocorticoid signaling has a predominant
effect in the modulation of cardiac electrical activity.
We found that long-termadrenalectomy (6mo) leads to
cardiac dysfunction with a significant decrease in FS. Par-
alleling the observed functional deficit, histological eval-
uation of hearts from 6-month ADX mice showed an in-
crease in thicknessof theLVwall and in the cardiomyocyte
cross-sectional area. These data are in agreement with re-
cent studies byOakley et al, which showed thatmice lack-
ing GR signaling in cardiomyocytes (cardio GRKO) de-
velop spontaneous cardiac hypertrophy and heart failure
(22). Thus, removal of the hormones that activate both the
GR and the MR leads to a similar phenotype in the heart.
Our previous study showed that loss of cardiac GR
signaling results in aberrant regulation of a large cohort of
genes associated with abnormal calcium handling in car-
diac hypertrophy and heart failure (22).Moreover,mouse
models overexpressingMR in the heart have also demon-
strated that mineralocorticoid signaling has effects on L-
type calcium channel activity in cardiomyocytes (34). In
vivo aldosterone infusion promotes the occurrence of
widespread and long-lasting Ca2 sparks due to an in-
crease in the activity of cardiomyocyte RYRs (18). In ad-
dition, recent studies byMessaoudi et al showed that MR
activation in the heart leads to alterations in the gene ex-
pression of ion channels, including potassium large con-
ductance Ca2-activated channel, subfamily M, -mem-
ber 4, potassium channel, subfamily V, member 2, and
Ca2 channel, voltage-dependent, l-type, 1S subunit
(32). Consistently, hearts fromADXmice presented a sig-
nificant dysregulation in a large cohort of cardiovascular
disease genes associated with ventricular tachycardia and
heart rhythm disorders, including Brugada syndrome, a
disorder associated with mutations in genes involved in
ion transport including sodium, potassium and calcium
channels, with a characteristic prolongation of QT inter-
vals (35). Thus, our genome wide gene expression results
correlate well with the current literature (32).
In agreement with the changes in gene expression ob-
served inADXhearts, long-termadrenalectomyalso led to
ECG abnormalities characterized by prolonged QT inter-
vals. These findings are consistent with in vivo studies
showing that both GR andMR play a role in the etiology
of atrio-ventricular alterations and ventricular arrhyth-
mias in mice (34, 36).
To rule out the possibility that sodium in drinking wa-
terwas contributing to the cardiac phenotype observed on
the ADX hearts, functional studies were performed on
control (intact) and sham-ADX mice drinking 0.154M
NaCl. No significant alterations in BP, LV function, or
ECG measurements were found associated with the
0.154M sodium chloride drinking water, suggesting that
corticosteroid deficiency is important in the cardiovascu-
lar phenotype observed in ADX mice.
In an attempt to differentiate the effects of glucocorti-
coids andmineralocorticoids in ourmodel, C57BL/6male
mice were ADX at 1 month of age and followed by re-
placement with corticosterone, betamethasone (a gluco-
corticoid lacking MR activity), and aldosterone (17, 29–
31). Data from these studies revealed that, despite the
effects of glucocorticoids on growth, body weight and
liver chemistry (Supplemental Table 5), corticosterone
and betamethasone replacement treatment prevented
LVD in ADX mice. Similar results were obtained in mice
treated with the combination of corticosterone and aldo-
sterone. In contrast, treatment with aldosterone alone
does not prevent LVD, suggesting that glucocorticoid sig-
naling is playinga critical role in restoring cardiac function
inourmodel. Provocatively, aldosteronewas able toblock
the emergence ECG alterations in ADX mice either as a
single treatment or in combination with corticosterone,
despite the reduction in plasma potassium levels observed
in aldosterone-treated ADX mice. Therefore, our data
suggest that at the dose administered in our study, corti-
costerone activates GR-dependent processes in the heart;
however, it does not mimic aldosterone effects in terms of
heart electrical conduction. Furthermore corticosterone
neither activates nor antagonizes aldosterone actions at
the sinoatrial nodal MR when they are coadministered.
Together, our results demonstrate that glucocorticoids
and mineralocorticoids have selective actions in the heart
even in the context of the whole animal.
Given the fact that glucocorticoids bind GR and MR,
the physiology underlying tissue-specific actions of gluco-
corticoid is complex. Corticosterone has been reported to
have 10- to 30-fold lower affinity for GR thanMR, and in
classic target tissues such as the distal nephron, MR se-
lectivity is achieved by the coexpression of 11-hydrox-
ysteroid dehydrogenase type 2 (37). Cardiomyocytes do
not express 11-hydroxysteroid dehydrogenase type 2;
therefore glucocorticoids are not inactivated in the heart
and can likely interact with MR (17). In addition, plasma
levels of glucocorticoids are 1000 times greater than those
of aldosterone suggesting that MR in cardiomyocytes are
predominantly occupied by glucocorticoids (38). To gain
insights into the role of GR and MR ligands in normal
cardiac physiology, we used adrenalectomy as a model of
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adrenal insufficiency. Clearly, this study does not differ-
entiate between glucocorticoids and mineralocorticoids
acting directly or indirectly in the heart. However, our
data are consistent with data from transgenicmousemod-
els of GR andMR that have shown thatGR is essential for
normal cardiac function and survival (22), whereas MR
signaling play an important role in the etiology of cardiac
arrhythmias (34). Future studies are needed to decipher
the molecular interplay betweenMR and GR signaling in
the cardiovascular system of both male and female mice.
In particular it will be essential to elucidate the direct and
indirect actions of GR and MR signaling in cardiomyo-
cytes in vivo.
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